Guides on bioPROTAC fundamentals, the AI design and wet-lab validation methodology behind the ProxAI engine, and how to evaluate a degrader discovery platform.
The definitional starting point — what a bioPROTAC is and how it differs from a conventional PROTAC.
A side-by-side comparison of mechanism, delivery, target scope, and development speed.
Why most drug discovery depends on a binding pocket, and what happens when a target doesn't have one.
How the dry-lab-to-wet-lab pipeline actually runs, from candidate generation to validated lead.
What FACS-based screening measures, and why it's the step that turns a prediction into a lead.
What a computational prediction can't tell you — and why cell-based confirmation still matters.
Unpacking the structural precision benchmark and what it says about design accuracy before wet-lab testing.
A framework for deciding whether to build discovery capability in-house or license a platform.
The questions worth asking before committing to a platform licensing or co-development deal.
